A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM | MicrobiomeTrials
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-30Est. Completion: 2029-02-23
Enrollment target: 326 participants
Locations
Research Site, La Jolla, California, United States
Research Site, San Francisco, California, United States
Research Site, Stanford, California, United States
Research Site, Aurora, Colorado, United States
Research Site, Washington D.C., District of Columbia, United States
Research Site, Jacksonville, Florida, United States
Research Site, Miami, Florida, United States
Research Site, Weston, Florida, United States
Research Site, Chicago, Illinois, United States
Research Site, Boston, Massachusetts, United States
Research Site, Kansas City, Missouri, United States
Research Site, St Louis, Missouri, United States
Research Site, New York, New York, United States
Research Site, Chapel Hill, North Carolina, United States
Research Site, Durham, North Carolina, United States
Research Site, Cleveland, Ohio, United States
Research Site, Portland, Oregon, United States
Research Site, Danville, Pennsylvania, United States
Other microbiome trials you might be interested in